KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Depreciation & Amortization (CF) (2020 - 2025)

Boston Scientific (BSX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $365.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.89% to $365.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 7.8% year-over-year, with the annual reading at $1.4 billion for FY2025, 7.8% up from the prior year.
  • Depreciation & Amortization (CF) hit $365.0 million in Q4 2025 for Boston Scientific, up from $342.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $365.0 million in Q4 2025 to a low of $263.0 million in Q2 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $303.1 million across 5 years, with a median of $299.0 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 4.36% in 2021 and later increased 11.76% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $290.0 million in 2021, then increased by 1.38% to $294.0 million in 2022, then grew by 6.46% to $313.0 million in 2023, then grew by 11.18% to $348.0 million in 2024, then rose by 4.89% to $365.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BSX at $365.0 million in Q4 2025, $342.0 million in Q3 2025, and $336.0 million in Q2 2025.